Abstract:Objective Glucocorticoid (GC) excess decreases bone mineralization and microarchitecture and lead to reduced bone strength. Both anabolic agent parathroid hormone (PTH) and anti-resorptive agent alendronate (ALN) are used to prevent and treat GC-induced bone loss, yet these bone active agents alter bone turnover by very different mechanisms. Our study was to determine how PTH and ALN alter bone quality following GC excess.Methods Nine-month-old SD male rats were treated with methylprednisolone (5 mg/kg·d) or placebo (CON). Other two groups of GC-treated rats had either PTH(80 μg/kg·d) or ALN(4 mg/kg·d) intervention. All the animals were killed after 3 months, and femur and tibia isolated for indicated detection. Bone quality and quantity measurements were measured by dual x-ray absorptiometry (DEXA) for the degree of bone mineralization, histomorphometry for bone microarchitecture, biochemistry for bone turnover. Osteoblasts isolated from newborn rats were cultured in vitro. Cells were treated with 1) CON: placebo; 2)GC: Dexamethasone 10-5mol/L; 3) ALN: Alendronate 10-7mol/L; 4)PTH: human recombinant parathyroid hormone 10-7mol/L; 5)GC+ALN: Dexamethasone 10-5mol/L+ALN 10-7mol/L; 6)GC+PTH: Dexamethasone 10-5mol/L+ PTH 10-7mol/L. Osteoblast proliferation and osteogenic activity were identified by MTT, alkaline phosphatase detection, calcium nodules were observed by Alizarin red staining, and real-time PCR were performed to monitor the expression of several key genes regulating bone formation and mineralization as FGF23 and SOST.Results Spine and Femur BMD was reduced after GC treatment, and it was restored to CON level with GC+ALN and GC+PTH at site of femur and spine separately (P<0.05). Compared to the CON, GC treatment decreased trabecular bone volume, bone formation rate, mineral apposition rate and serum BGP, but increased osteoclast surface and serum TRAP5b (P<0.05). GC+PTH increased and GC+ALN restored trabecular bone volume to the CON levels (P<0.05 compared to GC). GC+PTH increased bone formation rate and serum BGP compared to GC (P<0.05), while GC+ALN increased mineral apposition rate (P<0.01) and reduced osteoclast surface and serum TRAP5b compared to GC (P<0.05). As to osteoblasts experiments, GC treatment decrease MTT and AKP activity, reduced calcium nodules significantly (P<0.05 compared to CON), however, GC+PTH and GC+ALN promoted osteoblast MTT and AKP to the CON levels, but PTH significantly inhibited the calcium nodules, whereas ALN increased it. Realtime-PCR revealed that SOST and FGF23 were up-regulated by GC treatment (P<0.05 compared to CON), but SOST gene was down-regulated after GC+PTH treatment (P<0.01 compared to GC), while SOST and FGF23 genes were both down-regulated by GC+ALN treatment (P<0.05 compared to GC). Conclusion GC excess increased expression of gene that inhibit osteoblast activity and gene that inhibit mineralization and which were associated with reduced bone formation and bone volume. The addition of both PTH and ALN improved bone mass and bone strength during concurrent GC treatment, with PTH lowering expression of SOST and increasing bone formation; while ALN lowered the expression of SOST and FGF23 and reversed the deterioration of bone mineralization induced by GC excess.

Effect of amylin on bone metabolic biochemical indexes in glucocorticoid-induced osteoporosis rats

Effects of amylin on bone minernal density and structure parameters of bone tissue in glucocorticoid-induced osteoporosis rats

Effect of Amylin on Biomechanical Properties of the Femur in Glucocorticoid-Induced Osteoporosis Rats

Effect of Intermittent Fasting on Glucose Homeostasis and Bone Remodeling in Glucocorticoid-Induced Osteoporosis Rat Model

AB0845 Technetium-99 conjugated with methylene diphosphonate ameliorates glucocorticoid induced osteoporosis in rats

[Effects of Serum Containing Oral Liquid of Guilu-Erxian on the Therapy of Osteoporosis at the Cellular Level].

Relationships among magnetic resonance imaging, histological findings, and IGF-I in steroid-induced osteonecrosis of the femoral head in rabbits

Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats

Effect of antler extract on corticosteroid-induced avascular necrosis of the femoral head in rats.

Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density

Daphnetin ameliorates glucocorticoid-induced osteoporosis via activation of Wnt/GSK-3β/β-catenin signaling

Alleviation of Glucocorticoid-Induced Osteoporosis in Rats by Ethanolic Reynoutria multiflora (Thunb.) Moldenke Extract

Potential therapeutic targets of alendronate and PTH for glucocorticoid-induced bone loss

The effect of 1,25(OH)_2D_3 on bone metabolism in primary glomerulonephritis patients receiving glucocorticoid treatment

Effects of combined therapy of alendronate and low-intensity pulsed ultrasound on metaphyseal bone repair after osteotomy in the proximal tibia of glucocorticoid-induced osteopenia rats

Inhibition of PPARγ by bisphenol A diglycidyl ether ameliorates dexamethasone-induced osteoporosis in a mouse model

The Study of Cellular and Molecular Mechanism of the Combination Therapy Using Gukangling Decoction and Technetium[99tc] Methylene Diphosphonate for Glucocorticoid-Induced Osteoporosis

Effects of Cornel Total Glycoside on Bone Morphological Metrology in Ovariectomized Rats

Therapeutic Effect of Rhpth (1-34) on Glucocorticoid-Induced Osteoporosis in Rats

Effect of Gengnianchun Decoction on Bone Metabolism-Related Genes Expression in Bone Marrow Microenvironment

Effect of antiresorptive drugs on cortical bone of cynomolgus monkeys by histomorphometrical analysis